

---

---

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

**Form 8-K**

Current Report  
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): April 15, 2019

**FENNEC PHARMACEUTICALS INC.**

(Exact name of registrant as specified in its charter)

001-32295  
(Commission File Number)

British Columbia, Canada  
(State or other jurisdiction of  
incorporation)

20-0442384  
(I.R.S. Employer Identification No.)

PO Box 13628, 68 TW Alexander Drive,  
Research Triangle Park, NC  
(Address of principal executive offices)

27709  
(Zip Code)

Registrant's telephone number, including area code: (919) 636-4530

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

---

---

**Item 5.02      Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.**

(e)      In April 2019, the Compensation Committee of the Board of Directors of Fennec Pharmaceuticals Inc. (the “Company”) retained Radford, an Aon company (“Radford”), to provide assistance in reviewing the compensation of the Company’s officers and directors. In part on the basis of Radford’s recommendations, the Compensation Committee approved an increase to the annual base salary of the Company’s Chief Executive Officer, Rostislav Raykov, from \$350,000 to \$400,000, and an increase to the annual base salary of the Company’s Chief Financial Officer, Robert Andrade, from \$250,000 to \$290,000 commencing on the pay period ending April 15, 2019. Other than these salary increases, the compensation and employment terms for Messrs. Raykov and Andrade remain unchanged.

**SIGNATURE**

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

FENNEC PHARMACEUTICALS INC.

Date April 19, 2019

By: /s/ Rostislav Raykov

Rostislav Raykov  
Chief Executive Officer

---